Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stocks in this Quantisnow insightHealth Care
Historical context for NGNE
Across the 17 sessions after earlier NGNE headlines, the stock closed higher 6 times and lower 11 times, with a median move of 3.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NGNE | SPY |
|---|---|---|---|
| May 13, 2026 | Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates | +3.4% | +0.6% |
| May 12, 2026 | Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy | +2.1% | -0.2% |
| May 7, 2026 | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -3.3% | -0.3% |
| Apr 28, 2026 | Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy | +1.5% | -0.5% |
| Apr 20, 2026 | Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors | -0.4% | -0.2% |
| Apr 9, 2026 | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.1% | +0.6% |
Quantisnow market dataNASDAQ
NGNE
Neurogene Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for NGNE
Full NGNE profile on Quantisnow Follow NGNE and get a push notification the moment its next story breaks.